Zobrazeno 1 - 10
of 48
pro vyhledávání: '"M. DeLena"'
Autor:
V. Blanco-Gozalo, A. Blazquez-Medela, O. Garcia-Sanchez, Y. Quiros, M. Montero, C. Martinez-Salgado, F. Lopez-Hernandez, J. Lopez-Novoa, L. Yao, Z. Qing, X. Hua, F. Min, M. Fei, W. Ning, V. Cantaluppi, F. Figliolini, M. Delena, S. Beltramo, D. Medica, C. Tetta, G. Segoloni, L. Biancone, G. Camussi, J. S. Cunha, V. M. Ferreira, M. A. Naves, M. A. Boim, T. Zitman-Gal, E. Golan, J. Green, M. Pasmanik-Chor, J. Bernheim, S. Benchetrit, M. Riera, S. Clotet, J. Pascual, M. Soler, K. Nakai, H. Fujii, K. Kono, S. Goto, M. Hirata, M. Shinohara, M. Fukagawa, S. Nishi, Q. Fan, S. Du, Y. Jiang, L. Wang, L. Fang, T. Radovits, M. M. Mozes, L. Rosivall, G. Kokeny, R. Aoki, R. Tateoka, F. Sekine, K. Kikuchi, Y. Yamashita, Y. Itoh, L. Cappuccino, G. Garibotto, E. D'Amato, B. Villaggio, F. Gianiorio, M. Mij, F. Viazzi, G. Salvidio, D. Verzola, A. Piwkowska, D. Rogacka, I. Audzeyenka, M. Kasztan, S. Angielski, M. Jankowski, E. W. Gaber, H. A. El-Attar, J. Liu, W. Zhang, Y. He, E. Macsai, Z. Takats, L. Derzbach, A. Korner, B. Vasarhelyi, M. S. Huang, H. Bo, F. Liu, P. Fu, N. E. Tsotakos, E. C. Tsilibary, G. I. Drossopoulou, N. Thawho, N. Farid, A. Peleg, A. Levy, N. Nakhoul, A. R. Lenghel, G. Borza, C. Catoi, C. I. Bondor, A. Muresan, I. M. Kacso, J.-S. Song, J.-H. Song, S.-H. Ahn, B. S. Choi, Y. a. Hong, M. Y. Kim, J. H. Lim, K.-S. Yang, S. Chung, S. J. Shin, H. W. Kim, Y. S. Chang, Y. S. Kim, C. W. Park, K. Takayanagi, H. Hasegawa, T. Shimizu, A. Ikari, C. Noiri, T. Iwashita, Y. Tayama, J. Asakura, N. Anzai, K. Kanozawa, H. Kato, T. Mitarai, M. Huang, R. H. Ashour, A. E.-M. M. Fouda, M. A. Saad, F. M. El-Banna, F. A. Moustafa, M. I. Fouda, M. D. Sanchez-Nino, A. B. Sanz, J. Poveda, M. Saleem, P. Mathieson, M. Ruiz-Ortega, R. Selgas, J. Egido, A. Ortiz, M. J. Soler, M. Rebull, E. Marquez, S. Okazaki, Y. Kogure, T. Sano, M. Hatano, E. Kreft, R. Kowalski, M. Szczepansk-Konkel, X. Liu, G. Yang, N. A. Osman, M. M. NasrAllah, M. M. Kamal, A. I. Ahmed, N. Fekih-Mrissa, M. Mrad, A. Baffoun, A. Sayeh, J. Hmida, N. Gritli, V. Galchinskaya, I. Topchii, P. Semenovykh, N. Yefimova, D. Zheng, D. Hu, X. Li, A. I. Peng, N. Olea-Herrero, M. Arenas, C. Munoz-Moreno, R. Moreno-Gomez-Toledano, M. Gonzalez-Santander, I. Arribas, R. Bosch
Publikováno v:
Nephrology Dialysis Transplantation. 28:i374-i384
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b948cf8fb1ca2e1a89f65227ce9b98c1
https://doi.org/10.1093/ndt/gft137
https://doi.org/10.1093/ndt/gft137
Autor:
Bernardo Amadeo Leone, J. M. Romero Acuna, M A Cuevas, L. Romero Acuna, M Machiavelli, Vito Lorusso, S. Amato, M. R. Barbieri, A Romero, M. J. Langhi, E. H. Ortiz, R. Rodriguez, Manuel Domínguez, M. A. Salvadori, J E Perez, M. DeLena, Carlos Teodoro Vallejo, C. L. Sabatini, J. A. Lacava
Publikováno v:
American Journal of Clinical Oncology. 21:94-98
A phase II trial was performed to evaluate the efficacy and toxicity of a double modulation of 5-fluorouracil (5-FU) by methotrexate (MTX) and L-leucovorin (L-LV) in patients with advanced recurrent (inoperable) or metastatic colorectal carcinoma (AC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::475be8466be84efe598707480683ebd0
https://doi.org/10.1097/00000421-199802000-00022
https://doi.org/10.1097/00000421-199802000-00022
Autor:
Laura Masiero, Spiridione Garbisa, M. Correale, Wg Stetlerstevenson, M Delena, A. Leone, A. Paradiso, Cd Dragone, La Liotta
Publikováno v:
International Journal of Oncology. 4:551-554
The metastatic potential of cancer cells has been associated to their ability to elaborate and secrete basement membrane degradative enzymes. In this process a major role appears to be played by a protease known as gelatinase A (72 kDa type IV collag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5ae128c9a4ede4101954db54bf8f8cf
https://doi.org/10.3892/ijo.4.3.551
https://doi.org/10.3892/ijo.4.3.551
Publikováno v:
Oncology reports. 1(3)
Twenty-two women with metastatic breast cancer, previously submitted to one or more lines of chemotherapy, were treated with mitoxantrone as single agent delivered at full dosage (14 mg/m(2)) every other week (accelerated chemotherapy). This dose was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::112444898361bb6c85d427f125e6b16d
https://pubmed.ncbi.nlm.nih.gov/21607409
https://pubmed.ncbi.nlm.nih.gov/21607409
Publikováno v:
International journal of oncology. 3(2)
Immunotherapy represents a promising biological approach to cancer treatment. Important haemato-immunological modifications during rIL-2 treatment have been demonstrated in all patients treated, independently of the schedule and mode of rIL-2 adminis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac71ddb9bcdd9efb45c1d95de4ab9d64
https://pubmed.ncbi.nlm.nih.gov/21573344
https://pubmed.ncbi.nlm.nih.gov/21573344
Autor:
S, Tommasi, C, Rella, C, Giannella, M, Quaranta, F, Schittulli, A, Paradiso, M, Coviello, M, Delena
Publikováno v:
International journal of oncology. 5(3)
HER-2/neu status and t-PA, u-PA, and PAI-1 cytosol content were evaluated in 88 primary breast cancer patients to determine the relationships between these parameters. HER-2/neu was amplified in 24% (20/84) of tumor samples and overexpressed in 28% (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a48962402bedbcce8c93309d7f75124b
https://pubmed.ncbi.nlm.nih.gov/21559600
https://pubmed.ncbi.nlm.nih.gov/21559600
Autor:
Lorusso, M Cisternino, F Carpagnano, M Guida, M Delena, A Latorre, G diRienzo, M. Brandi, R Ricco, Annamaria Catino, S Parisi
Publikováno v:
Scopus-Elsevier
Thirty patients with marginally resectable stage IIIA or stage IIIB NSCLC were treated with cisplatin (80 mg/ m(2)/i.v./dl), ifosfamide (4,000 mg/m(2)/i.v./dl) and vinorelbine (30 mg/m(2)/i.v./dl) plus G-CSF 300 mu g/s.c. on days 7-12 every 14 days f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c3b1bca731ce259851fc9454c1ec411
https://pubmed.ncbi.nlm.nih.gov/21544412
https://pubmed.ncbi.nlm.nih.gov/21544412
Publikováno v:
International journal of oncology. 10(3)
The management of metastatic renal cell carcinoma (RCC) constitutes a therapeutic challenge and no standard therapy has yet been established. This phase II study aimed to verify the efficacy and tolerability of subcutaneous low dose recombinant inter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ec5b56686c7b6b9c3144cae8c760f95
https://pubmed.ncbi.nlm.nih.gov/21533401
https://pubmed.ncbi.nlm.nih.gov/21533401
Autor:
M Brandi, G. Palomba, Ar Bianco, Chiara Carlomagno, M. Lopez, Lorusso, Fosser, M. D'Aprile, M Delena, Patrizia Vici, Andrea Piano, S Deplacido
Publikováno v:
International Journal of Oncology. 2:531-535
A multicentric randomized study was conducted to compare the CNF regimen (cyclophosphamide at 600 mg/m2/iv, mitoxantrone at 10 mg/m2/iv, 5-fluorouracil at 600 mg/m2/iv) with the CMF regimen (methotrexate at 40 mg/m2/iv instead of mitoxantrone) admini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ceb4daf86ad02b02af4842adda67172d
https://doi.org/10.3892/ijo.2.4.531
https://doi.org/10.3892/ijo.2.4.531
Autor:
A, Daponte, P A, Ascierto, A, Gravina, M T, Melucci, G, Palmieri, P, Comella, R, Cellerino, M, DeLena, G, Marini, G, Comella
Publikováno v:
Cancer. 89(12)
In a previous study, the authors tested the combination of fotemustine (FM) 100 mg/m(2) intravenously (i.v.) on Day 1, dacarbazine (DTIC) 250 mg/m(2) i.v. on Days 2-5, and interferon alpha (IFNalpha) 3 MIU intramuscularly three times per week in 43 p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cb232d22859907a74cbe53797cd68bf6
https://pubmed.ncbi.nlm.nih.gov/11135225
https://pubmed.ncbi.nlm.nih.gov/11135225